Colin Berry
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Colin Berry has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- Samuel M. Cohen
Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE
5 shared publications - Wolfgang Dekant
Department of Pharmacology and Toxicology, University of Würzburg, Germany [Prof. (emeritus) of Toxicology
5 shared publications - Hiroshi Yamazaki
Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Tokyo, Japan
4 shared publications - James E. Klaunig
School of Public Health, Indiana University, Bloomington, IN, USA
4 shared publications - Alan R. Boobis
Imperial College London, London, UK
3 shared publications - Corrado Lodovico Galli
Università degli Studi di Milano
3 shared publications
Latest Publications
- Open Access
- 14 July 2026
- Published by Forschungsgesellschaft für Arbeitsphysiologie und Arbeitsschutz e.V. in EXCLI Journal
- Vol. 25, 1107-1116
Retraction of the landmark glyphosate safety publication by Williams, Kroes and Munro (2000) should be reversed
The decision by the co-Editor-in-Chief of Regulatory Toxicology and Pharmacology, Prof. Martin van den Berg, to retract the 2000 review article by Williams, Kroes, and Munro has elicited widespread criticism within the scientific community. Issued in late 2025, the retraction decision cites procedural concerns including potential ghostwriting, undisclosed conflicts of interest, and omission of certain unpublished studies, invoking Committee on Publication Ethics guidelines despite lacking evidence of fraud or scientific flaws. This editorial argues that the retraction decision involves editorial overreach and misapplication of the guidelines. The alleged omissions stemmed from proprietary data access limitations that were disclosed in the original paper. Subsequent reviews by several independent expert panels and regulatory authorities with access to all glyphosate data, including the studies cited by the retracting editor, reached similar conclusions. Claims of ghostwriting were previously investigated and found lacking, including a declaration by EFSA as to the clarity of the conflict disclosures. The retraction’s timing, reliance on litigation documents, and apparent biases that were not disclosed in the retraction notice raise questions of ideological interference. Absent substantive rebuttals based on scientific merit rather than speculative claims of inappropriate authorship and data access, this retraction decision sets a dangerous precedent for retroactive censorship, potentially chilling beneficial industry-academic collaborations and eroding trust in the integrity of scientific publishing. With the strongest conviction, we assert that retracting a paper without scientific flaws isn’t protection—it is censorship. We therefore call for the immediate reversal of this flawed and unjustified retraction to preserve trust in peer-reviewed literature.
- 14 July 2026
- Published by Forschungsgesellschaft für Arbeitsphysiologie und Arbeitsschutz e.V. in EXCLI Journal
- Vol. 25, 1107-1116
Open AccessRetraction of the landmark glyphosate safety publication by Williams, Kroes and Munro (2000) should be reversed
The decision by the co-Editor-in-Chief of Regulatory Toxicology and Pharmacology, Prof. Martin van den Berg, to retract the 2000 review article by Williams, Kroes, and Munro has elicited widespread criticism within the scientific community. Issued in late 2025, the retraction decision cites procedural concerns including potential ghostwriting, undisclosed conflicts of interest, and omission of certain unpublished studies, invoking Committee on Publication Ethics guidelines despite lacking evidence of fraud or scientific flaws. This editorial argues that the retraction decision involves editorial overreach and misapplication of the guidelines. The alleged omissions stemmed from proprietary data access limitations that were disclosed in the original paper. Subsequent reviews by several independent expert panels and regulatory authorities with access to all glyphosate data, including the studies cited by the retracting editor, reached similar conclusions. Claims of ghostwriting were previously investigated and found lacking, including a declaration by EFSA as to the clarity of the conflict disclosures. The retraction’s timing, reliance on litigation documents, and apparent biases that were not disclosed in the retraction notice raise questions of ideological interference. Absent substantive rebuttals based on scientific merit rather than speculative claims of inappropriate authorship and data access, this retraction decision sets a dangerous precedent for retroactive censorship, potentially chilling beneficial industry-academic collaborations and eroding trust in the integrity of scientific publishing. With the strongest conviction, we assert that retracting a paper without scientific flaws isn’t protection—it is censorship. We therefore call for the immediate reversal of this flawed and unjustified retraction to preserve trust in peer-reviewed literature.
- Open Access
- 30 January 2025
- Published by SAGE Publications in Human & Experimental Toxicology
- Vol. 44
Conflicts of interest in the International Agency for Research on Cancer process of identifying carcinogenic hazards to humans
Managing conflicts of interest (COIs) in scientific decision-making is important for minimizing bias and fostering public trust in science. Proper management of COIs has added significance when scientists are making decisions that impact public policy, such as assessing substances for carcinogenicity. The International Agency for Research on Cancer (IARC) organizes expert working groups to identify putative carcinogens and determine whether or not the hazard is likely to present significant potential harm to humans. While IARC has policies for managing COIs, prior professional experience with the substance being assessed is not defined as a COI. Indeed, IARC working group members are chosen based on subject matter expertise, including prior publication on the substance under review. However, a person’s prior experience with a substance poses a significant potential COI by equipping them with strong pre-existing views about the substance’s toxicity and carcinogenicity. To minimize the risk of bias in IARC working groups, participants with voting powers should be independent scientific experts with sufficient professional experience to review carcinogenicity data but with no substantial prior experience with the substance under review. A related IARC practice restricting data review by working groups to selected publications is another significant COI. Instead, all accessible data should be available for consideration by working groups in assessing the carcinogenic hazard of substances. Another recommendation to reduce potential bias would be to reinstate the option of “probably not carcinogenic to humans”.
- 30 January 2025
- Published by SAGE Publications in Human & Experimental Toxicology
- Vol. 44
Open AccessConflicts of interest in the International Agency for Research on Cancer process of identifying carcinogenic hazards to humans
Managing conflicts of interest (COIs) in scientific decision-making is important for minimizing bias and fostering public trust in science. Proper management of COIs has added significance when scientists are making decisions that impact public policy, such as assessing substances for carcinogenicity. The International Agency for Research on Cancer (IARC) organizes expert working groups to identify putative carcinogens and determine whether or not the hazard is likely to present significant potential harm to humans. While IARC has policies for managing COIs, prior professional experience with the substance being assessed is not defined as a COI. Indeed, IARC working group members are chosen based on subject matter expertise, including prior publication on the substance under review. However, a person’s prior experience with a substance poses a significant potential COI by equipping them with strong pre-existing views about the substance’s toxicity and carcinogenicity. To minimize the risk of bias in IARC working groups, participants with voting powers should be independent scientific experts with sufficient professional experience to review carcinogenicity data but with no substantial prior experience with the substance under review. A related IARC practice restricting data review by working groups to selected publications is another significant COI. Instead, all accessible data should be available for consideration by working groups in assessing the carcinogenic hazard of substances. Another recommendation to reduce potential bias would be to reinstate the option of “probably not carcinogenic to humans”.
- Open Access
- 1 April 2020
- Published by Wiley in Pest Management Science
- Vol. 76 (9) , 2874-2877
Glyphosate and cancer: the importance of the whole picture
This commentary does not concern itself with the need for, or the value of glyphosate as an agrochemical: rather it examines the scientific basis for the various conclusions reached at different times by a number of regulatory authorities and by the International Agency on Research on Cancer (IARC). Why do they differ? An appropriate regulatory stance depends critically on the application of good science and consistency in the application of established criteria. Constant reappraisal of the methodology used is essential. © 2020 The Author. Pest Management Science published by John Wiley & Sons Ltd on behalf of Society of Chemical Industry.
- 1 April 2020
- Published by Wiley in Pest Management Science
- Vol. 76 (9) , 2874-2877
Open AccessGlyphosate and cancer: the importance of the whole picture
This commentary does not concern itself with the need for, or the value of glyphosate as an agrochemical: rather it examines the scientific basis for the various conclusions reached at different times by a number of regulatory authorities and by the International Agency on Research on Cancer (IARC). Why do they differ? An appropriate regulatory stance depends critically on the application of good science and consistency in the application of established criteria. Constant reappraisal of the methodology used is essential. © 2020 The Author. Pest Management Science published by John Wiley & Sons Ltd on behalf of Society of Chemical Industry.
- Open Access
- 1 January 2020
- Published by SAGE Publications in Toxicology Research and Application
- Vol. 4
Frameworks for evaluation and integration of data in regulatory evaluations: The need for excellence in regulatory toxicology
Following a number of published expressions of concern about the reliability of experimental science and the implications of non-reproducibility for regulatory toxicology, the European Risk Forum undertook to consider what practises might improve the basis on which regulatory decisions might be made. Guidelines which may be useful in assessments are presented. The document acknowledges the value of the experimental standards used in most regulatory studies but indicates how these may fail to provide the ‘best outcome’ and how imperfect studies based on outdated views of pathophysiology of disease in H. Sapiens may offer little of predictive value.
- 1 January 2020
- Published by SAGE Publications in Toxicology Research and Application
- Vol. 4
Open AccessFrameworks for evaluation and integration of data in regulatory evaluations: The need for excellence in regulatory toxicology
Following a number of published expressions of concern about the reliability of experimental science and the implications of non-reproducibility for regulatory toxicology, the European Risk Forum undertook to consider what practises might improve the basis on which regulatory decisions might be made. Guidelines which may be useful in assessments are presented. The document acknowledges the value of the experimental standards used in most regulatory studies but indicates how these may fail to provide the ‘best outcome’ and how imperfect studies based on outdated views of pathophysiology of disease in H. Sapiens may offer little of predictive value.
- Open Access
- 22 November 2018
- Published by Springer Nature in Archives of Toxicology
- Vol. 93 (1) , 209
The dangers of preemptive obedience to political pressure and media campaigns in science
- 22 November 2018
- Published by Springer Nature in Archives of Toxicology
- Vol. 93 (1) , 209
Open AccessThe dangers of preemptive obedience to political pressure and media campaigns in science
- Open Access
- 11 July 2018
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 97, A1-A3
Obfuscating transparency?
- 11 July 2018
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 97, A1-A3
Open AccessObfuscating transparency?
- Open Access
- 10 January 2018
- Published by Oxford University Press (OUP) in Toxicology Research
- Vol. 7 (4) , 553-557
The failure of rodent carcinogenesis as a model for Man
Recent advances in our understanding of the process of carcinogenesis in Man have required revision of our thinking about the classical initiation/promotion sequence; understanding must now encompass the roles of both genetic and epigenetic change, realisation of the importance of the variable genetic backgrounds of the tumour bearers in any group and an understanding of the importance of random genetic events over time. The behavior of tumours, once established, is more complex than has been thought. Current views of the processes involved are not modelled in toxicity testing programmes.
- 10 January 2018
- Published by Oxford University Press (OUP) in Toxicology Research
- Vol. 7 (4) , 553-557
Open AccessThe failure of rodent carcinogenesis as a model for Man
Recent advances in our understanding of the process of carcinogenesis in Man have required revision of our thinking about the classical initiation/promotion sequence; understanding must now encompass the roles of both genetic and epigenetic change, realisation of the importance of the variable genetic backgrounds of the tumour bearers in any group and an understanding of the importance of random genetic events over time. The behavior of tumours, once established, is more complex than has been thought. Current views of the processes involved are not modelled in toxicity testing programmes.
- 1 December 2016
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 82, A1-A2
Whither the impending european regulation of presumed endocrine disruptors?
- 1 December 2016
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 82, A1-A2
Whither the impending european regulation of presumed endocrine disruptors?
- 1 September 2016
- Published by Elsevier in Toxicology
- Vol. 371, 12-16
Upholding science in health, safety and environmental risk assessments and regulations
- 1 September 2016
- Published by Elsevier in Toxicology
- Vol. 371, 12-16
Upholding science in health, safety and environmental risk assessments and regulations
- Open Access
- 1 September 2016
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 257, 1-3
Allowing pseudoscience into EU risk assessment processes is eroding public trust in science experts and in science as a whole: The bigger picture
- 1 September 2016
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 257, 1-3
Open AccessAllowing pseudoscience into EU risk assessment processes is eroding public trust in science experts and in science as a whole: The bigger picture